NCT01802931View on ClinicalTrials.gov

GSK239512 DDI Study

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

January 7, 2013

Primary Completion Date

April 15, 2013

Study Completion Date

April 15, 2013

Conditions
Multiple Sclerosis
Interventions
DRUG

GSK239512

H3 receptor antagonist, potential victim of drug-drug interaction

DRUG

ketoconazole

CYP3A4 inhibitor, potential perpetrator of drug-drug interaction

Trial Locations (1)

2031

GSK Investigational Site, Randwick

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01802931 - GSK239512 DDI Study | Biotech Hunter | Biotech Hunter